As the Maryland General Assembly is currently in session from January 10th through April 8th, a broad range of senate and house bills are moving through the legislative branch. Several relate to substance use, harm reduction, and healthcare funding. IRIS has summarized the currently pending House Bill 1268 (HB 1268) and withdrawn Senate Bill 497 (SB 497). Both bills relate to statewide naloxone accessibility. As IRIS continues to promote evidence-based treatment and recovery supports for opioid use disorder, we encourage advocates and policymakers to utilize research which supports increased naloxone access. As naloxone is an effective medication for opioid overdose reversal (Center for Disease Control, 2023), reducing barriers to access is vital. With 2,230 unintentional opioid overdose deaths in Maryland in 2022 (Maryland Department of Health, 2023), there is an urgent need for proven, life-saving tools such as naloxone.
|